Skip to main content
. 2014 Feb 25;22(4):828–841. doi: 10.1038/mt.2013.300

Figure 4.

Figure 4

Gint4.T inhibits GBM cell survival and proliferation. T98G (a) and U87MG (b) cells were mock-treated or treated for 24 hours with increasing amounts of Gint4.T, CL4 or the unrelated aptamer as a negative control, or with 200 nmol/l final concentration of each aptamer for the indicated incubation times (inserts). Cell viability was analyzed and expressed as percent of viable treated cells with respect to mock-treated cells. (a, b) P values for Gint4.T and CL4 relative to unrelated are: ***P < 0.0001; **P < 0.005; *P < 0.05 (n = 6). Error bars depict means ± SD. T98G (c) and U87MG (d) cells were treated for 72 hours with Gint4.T or the unrelated aptamer, as indicated. Cell-cycle profile were determined by BrdU incorporation and PI staining. Percentages of cells in each cycle phase are indicated. BrdU, anti-5-bromodeoxyuridine; PI, propidium iodide.